ML-104
Treatment-resistant Depression
PreclinicalLead optimization
Key Facts
Indication
Treatment-resistant Depression
Phase
Preclinical
Status
Lead optimization
Company
About MapLight Therapeutics
MapLight Therapeutics is focused on transforming the treatment of brain disorders by developing precision medicines that target specific dysfunctional neural circuits. The company's MAP (Molecular and Anatomical Phenotyping) platform integrates advanced neuroscience tools to deconstruct complex behaviors and identify novel therapeutic targets. With a lead program in Phase 2 for autism spectrum disorder and a pipeline of preclinical candidates, MapLight is advancing a new generation of neuropsychiatric drugs. The company went public in 2024 and is positioned to address significant unmet needs in neurology and psychiatry.
View full company profileTherapeutic Areas
Other Treatment-resistant Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| JNJ-1802 | Johnson & Johnson | Phase 2 |
| DSP-6745 | Sumitomo Pharma | Phase 1 |
| PSG-301 | PharmaSGP | Preclinical |